Release Date: September 4, 2025
Expiration Date: September 4, 2026
Activity Overview
The management of extensive-stage small cell lung cancer (ES-SCLC) is poised to change substantially with recent practice-changing trial data. However, unmet needs remain, particularly with respect to optimizing disease biomarkers and novel treatment options.
This podcast features a discussion about the current standard of care in terms of unmet needs and developmental options for the management of ES-SCLC. Led by Rohit Gosain, MD; and Rahul Gosain, MD, this session features faculty experts in evaluating and treating SCLC.
Target Audience
This educational activity is for medical oncologists, nurse practitioners, physician assistants, and oncology nurses who manage patients with SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess efficacy data for conventional front-line and second-line treatments of ES-SCLC
- Recognize the unmet clinical needs in SCLC and potential opportunities to improve patient outcomes
Rahul Gosain, MD, MBA
Assistant Professor of Clinical Medicine
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Wilmot Cancer Institute–Webster
University of Rochester Medicine
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Assistant Professor of Clinical Medicine
University of New York at Buffalo
Director of Roswell Park Care Network Southtowns
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Giannis Mountzios ΜD, PhD
Director
4th Oncology Clinic and Clinical Trials Department
Henry Dunant Hospital Center
Athens, Greece
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Amgen, BMS, Daiichi Sankyo, Demo, GSK, MSD, Merk, Novartis, Roche, Summit Therapeutics, Takeda
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here